140 related articles for article (PubMed ID: 33953346)
41. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
42. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
43. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
44. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
[TBL] [Abstract][Full Text] [Related]
45. Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer.
Nagasu S; Sudo T; Kinugasa T; Yomoda T; Fujiyoshi K; Shigaki T; Akagi Y
Oncol Rep; 2019 May; 41(5):2889-2896. PubMed ID: 30864697
[TBL] [Abstract][Full Text] [Related]
46. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer.
Liu X; Liu L; Ji Y; Li C; Wei T; Yang X; Zhang Y; Cai X; Gao Y; Xu W; Rao S; Jin D; Lou W; Qiu Z; Wang X
EBioMedicine; 2019 Mar; 41():345-356. PubMed ID: 30857943
[TBL] [Abstract][Full Text] [Related]
47. The Significance of Circulating Tumour Cells in the Clinic.
Abalde-Cela S; Piairo P; Diéguez L
Acta Cytol; 2019; 63(6):466-478. PubMed ID: 30820013
[TBL] [Abstract][Full Text] [Related]
48. Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.
Katafygiotis P; Sakellariou S; Chatziandreou I; Giannopoulou I; Thymara I; Saetta AA; Korkolopoulou P
Anticancer Res; 2019 Nov; 39(11):6379-6387. PubMed ID: 31704871
[TBL] [Abstract][Full Text] [Related]
49. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
50. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
51. Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.
Li J; Dong W; Liu LN; Huang YJ; Xiao MF
Future Oncol; 2021 Jan; 17(1):81-90. PubMed ID: 32988235
[No Abstract] [Full Text] [Related]
52. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.
Serebriiskii IG; Connelly C; Frampton G; Newberg J; Cooke M; Miller V; Ali S; Ross JS; Handorf E; Arora S; Lieu C; Golemis EA; Meyer JE
Nat Commun; 2019 Aug; 10(1):3722. PubMed ID: 31427573
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
54. Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients.
Mondelo-Macía P; Rodríguez-López C; Valiña L; Aguín S; León-Mateos L; García-González J; Abalo A; Rapado-González O; Suárez-Cunqueiro M; Díaz-Lagares A; Curiel T; Calabuig-Fariñas S; Azkárate A; Obrador-Hevia A; Abdulkader I; Muinelo-Romay L; Diaz-Peña R; López-López R
Cells; 2020 Feb; 9(2):. PubMed ID: 32102486
[TBL] [Abstract][Full Text] [Related]
55. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
[TBL] [Abstract][Full Text] [Related]
56. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
[TBL] [Abstract][Full Text] [Related]
57. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
58. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
59. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
60. Liquid Biopsy: A New Tool in Oncology.
Costa JL; Schmitt FC
Acta Cytol; 2019; 63(6):448. PubMed ID: 31266005
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
